Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs for the blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma as early as first relapse.
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs, which are designed to target and degrade specific proteins involved in the disease.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs targeting this blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This approval marks a significant milestone as it is the first for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's first CELMoD therapy, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase for patients with multiple myeloma. This marks a significant milestone as it is the first approval for a new class of protein-degrading drugs aimed at treating this advanced blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.
US FDA approves Bristol Myers' blood cancer treatment
Lawsuit against Bristol Myers over delayed cancer drug is revived
Bristol Myers to build $2.3 billion manufacturing site in Houston
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca shares tumble 7% after reported Bristol Myers talks
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports
Bristol-Myers Boosts 2026 Guidance on Portfolio Strength